Anti-cancer immunotherapeutics
    7.
    发明授权
    Anti-cancer immunotherapeutics 失效
    抗癌免疫治疗

    公开(公告)号:US5693522A

    公开(公告)日:1997-12-02

    申请号:US371922

    申请日:1995-01-11

    摘要: The present invention provides a method of destroying selected tumor cells comprising administering to a warm-blooded animal a vector construct which directs the expression of at least one immunogenic, non-tumorigenic form of an altered cellular component normally associated with the selected tumor cells. Also provided are vector constructs which direct the expression of altered cellular components. Representative altered cellular components include ras.sup.*, p53.sup.*, Rb.sup.*, alter protein encoded by the Wilms' tumor gene, ubiquitin.sup.*, mucin.sup.*, DCC, APC, MCC, neu, an altered receptor, and bcr/abl. Also provided are recombinant viruses carrying a vector construct, target cells infected with the recombinant virus, and pharmaceutical compositions comprising the recombinant virus and a pharmaceutically acceptable carrier or diluent.

    摘要翻译: 本发明提供了破坏所选择的肿瘤细胞的方法,包括向温血动物施用指导至少一种免疫原性,非致瘤性形式的通常与所选择的肿瘤细胞相关的改变的细胞组分的载体构建体。 还提供了引导改变的细胞组分的表达的载体构建体。 代表性改变的细胞成分包括由Wilms肿瘤基因编码的ras *,p53 *,Rb *,改变的蛋白质,泛素*,粘蛋白*,DCC,APC,MCC,neu,改变的受体和bcr / abl。 还提供携带载体构建体的重组病毒,用重组病毒感染的靶细胞,以及包含重组病毒和药学上可接受的载体或稀释剂的药物组合物。